Specifically, symptomatic treatments such as acetylcholinesterase inhibitors have been available for over 20 years, approved by both the Food and Drug Administration (FDA) and the European Medicine Agency (EMA), for use in cognitive impairment due to AD, mixed vascular AD, and in the case of synucleinopathies. This evidence concerns the gene ACHE and Alzheimer disease.